Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Por Griffiths, C.E.M., Vender, R., Sofen, H., Kircik, L., Tan, H., Rottinghaus, S.T., Bachinsky, M., Mallbris, L., Mamolo, C.
Publicado no J Eur Acad Dermatol Venereol (2016)

Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of ox...

Por Eichenfield, L.F., Del Rosso, J.Q., Tan, J.K.L., Hebert, A.A., Webster, G.F., Harper, J., Baldwin, H.E., Kircik, L.H., Stein‐Gold, L., Kaoukhov, A., Alvandi, N.
Publicado no Br J Dermatol (2019)

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)...

Por Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J.‐P., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., Lesiak, A., Kircik, L., Cho, S.H., Herranz, P., Cork, M.J., Peris, K., Steffensen, L.A., Bang, B., Kuznetsova, A., Jensen, T.N., Østerdal, M.L., Simpson, E.L.
Publicado no Br J Dermatol (2020)